Abbott India: Modest growth - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Abbott India: Modest growth

Oct 3, 2003

MNC pharma major, Abbott India has recently announced its 3QFY04 results. While the company registered a modest 7% increase in topline, bottomline shot up by a significant 60%. For 9mFY04, Abbot registered a 5% growth in net sales and 29% rise in net profits. In this context, let us briefly evaluate the company’s performance.

Steady growth…
(Rs m)3QFY033QFY04Change9mFY039mFY04Change
Net Sales9691,0417.4%2,6322,7544.6%
Other Income202312.2%11715229.0%
Total expenditure7497804.2%2,0652,1443.8%
Operating Profit (EBDIT)22026118.4%5676107.5%
Operating Profit Margin (%)22.7%25.1% 21.6%22.2% 
Profit before Tax22527321.2%64273013.7%
Extra-ordinary items(31)0 -100.0%-310-100.0%
Profit after Tax/(Loss)12319660.3%41353128.7%
Net profit margin (%)12.6%18.9% 15.7%19.3% 
No. of Shares (m)16.215.3 16.215.3 
Earnings per share*30.251.4 34.046.4 
P/E ratio 6.6  7.3 

During 3QFY04, the domestic pharma industry has seen a revival in demand. However, the industry has still not witnessed its traditional double-digit growth rates. In line with the industry performance, Abbott India has managed to register a modest growth its topline. The growth was fuelled by the company’s strong anti-diabetics portfolio. On the operations front, a drop in the raw material cost and other expenditure by 2 percentage points and 1 percentage point respectively has helped Abbott India improve its operating margins. This coupled with a drop in the depreciation provisioning has resulted in the company recording a sharp 60% growth in the bottomline. However, it is to be noted here that in 3QFY03 last year, the company had reported for extra-ordinary loss of Rs 31 m on the sale of its Jejuri undertaking. If the same is excluded, the net profit growth drops to 28% YoY.

For 9mFY04, Abbott India’s performance was affected by the slowdown in the domestic market and the VAT fiasco. Infact, the company recorded stagnant/negative growth in most therapeutic segments other than the anti-diabetics segment. Resultantly, the topline grew by 5% and the bottomline by 29%. However, here again, if the losses booked during 9mFY03 in relation to the sale of the Jejuri undertaking are ignored, the net profit growth becomes 20%.

As was mentioned earlier, Abbott India has a strong presence in the anti-diabetics segment with animal insulins being its major product. Recently, Wockhardt had launched recombinant human insulins at low prices. This could affect Abbott India’s performance going forward as human insulins might be preferred to animal insulins by users who were earlier averse to the switchover on account of the high prices of human insulins. Another major concerning factor is Abbott India’s large exposure to DPCO. This has affected the company’s ability to fix prices and consequently stunted its topline growth. Recently, National Pharmaceuticals Pricing Authority (NPPA) ruling resulted in reduction of 3 Abbot products. This is likely to affect the performance of the company in the near term.

NPPA effect…
Formulation/Composition NamePack SizeExisting Price (Rs.)Revised Price (Rs.)Change (%)
Erykid-125 DIS Tablet 10's Blister18.015.1(16.3)
Erythromycin Ethyl Succinate Tablet 6's Al_St45.335.8(21.1)
Erythromycin Ethyl Succinate Tablet 6's Al_Bl45.035.5(21.2)

At Rs 338, Abbott India is trading at a P/E of 7x its 9mFY04 earnings. A high DPCO cover and competition led drop in human insulins prices could affect the performance of the company in the near term. Further, absence of product patents and a consequent reluctance by the parent in launching new products has affected company’s growth in the past. However, with product patents being introduced post 2005, things could improve. With the domestic pharma market now showing signs of recovery, we remain optimistic about the prospects of the company given the fact that it recorded a 6% growth in revenues in August ’03.

Equitymaster requests your view! Post a comment on "Abbott India: Modest growth". Click here!


More Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY22); Net Profit Up 8.5% (Quarterly Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

For the quarter ended June 2021, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 8.5% YoY). Sales on the other hand came in at Rs 12 bn (up 14.4% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA 2020-21 Annual Report Analysis (Annual Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

Here's an analysis of the annual report of ABBOTT INDIA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of ABBOTT INDIA. Also includes updates on the valuation of ABBOTT INDIA.

ABBOTT INDIA Announces Quarterly Results (4QFY21); Net Profit Up 37.4% (Quarterly Result Update)

Jul 8, 2021 | Updated on Jul 8, 2021

For the quarter ended March 2021, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 37.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 2, 2021 12:56 PM


  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks